All In Biotech

Drug Trial Radar · NCT07768124

Acupoint Application for Chemotherapy-Induced Nausea and Vomiting in Lung Cancer

Acupoint Application Combined With 5-HT3 Receptor Antagonist for Chemotherapy-Induced Nausea and Vomiting in Lung Cancer Patients: A Single-Center, Randomized, Controlled Trial

Last checked: Nov 20, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Jul 15, 2026

Primary completion

Oct 15, 2026

Study completion Oct 15, 2026

Sponsor

Lead sponsor
Xiu HuangAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Supportive care
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This single-center, randomized, controlled study evaluates whether acupoint application added to standard 5-HT3 receptor antagonist anti-nausea medication improves control of chemotherapy-induced nausea and vomiting in adults with lung cancer receiving first-line platinum-based chemotherapy. Participants will be randomly assigned to receive either acupoint application plus a 5-HT3 receptor antagonist or the 5-HT3 receptor antagonist alone for one chemotherapy cycle. The study will compare complete control of delayed nausea and vomiting between the two groups.

Conditions

  • Lung Cancer (Diagnosis)Chemotherapy-Induced Nausea and Vomiting

Interventions

  • 5-HT3 receptor antagonist (e.g., ondansetron)Drug

    Standard antiemetic prophylaxis for chemotherapy-induced nausea and vomiting.

  • Acupoint applicationOther

    Herbal plaster applied to selected acupoints to alleviate chemotherapy-induced nausea and vomiting.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete response rate of delayed-phase CINV (24-120 h)Time frame: 24 to 120 hours after the first cycle of platinum-based chemotherapy (each cycle is 21-28 days)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Affiliated Yongchuan Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.